Form D · Biotechnology
NovaDerm Aid Fund VII L.L.C.
Dallas, TX · CIK 0001973751
Offering snapshot reported Apr 17, 2023 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Dec 10, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 17, 2023 | Initial | $2,000,000 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $140K
- Finders' fees
- $180K
- Form D file number
- 021-478996
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Benchmark Investments, LLC | 103792 | Benchmark Investments, LLC · CRD 103792 |
| Mark Bianchi | None |
Source: Form D, filed Apr 17, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Geoffrey C. Dietrich | Executive |
| Biomed Management Alpha Llc | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4514 Cole Avenue, Suite 600
Dallas, TX, 75205
Dallas, TX, 75205